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In this issue of Neuron, two papers (Lim et al., 2013; Yu et al., 2013) use whole-exome sequencing (WES) to
elucidate the contribution of inherited variation to the risk for autism by leveraging the increased penetrance
of homozygous and compound heterozygous rare variants in autosomes and hemizygous rare variants in the
X chromosome of males. Together, they expand our knowledge about the genetic architecture of ASD, verify
previously identified genes, and identify novel mutations that will guide the discovery of the critical biological
processes disrupted in autism.Autism is a spectrum of neurodevelop-
mental disorders (referred to as autism
spectrum disorder, ASD) affecting around
1 in 88 individuals (2012 CDC estimate).
Genetic risk factors for ASD play
a substantial role and come in many
forms: those transmitted from parents to
affected child or those appearing de
novo in the germline, as well as those
found commonly in the population, or
those only rarely observed (Figures 1
and 2). Genetic investigations have re-
vealed that hundreds of genomic loci are
likely involved and it is now important to
advance our understanding of ASD’s
genetic architecture while simultaneously
identifying specific deleterious variants
to understand the biological pathways
involved (Berg and Geschwind, 2012).
Inherited variation from both common
and rare alleles provides the largest
genetic contribution to population-wide
ASD risk, explaining 40% (95% confi-
dence interval: 8%–84%) of the risk for
developing ASD (Hallmayer et al., 2011).
Though common variants are estimated
to be a large driving factor for the disorder
(40%–60% variance explained; Klei et al.,
2012), the effect size of individual
common variants is small (estimated to
be odds-ratio < 1.2; Anney et al., 2012).
This observation has led to a search for
rare variants, which may exhibit larger
individual effect sizes.
To this end, cost-effective high-
throughput genome sequencing of ASD
patients analyzed in paradigms where
the effect of a mutation can be seen over
random chance plays a critical role (Iossi-fov et al., 2012; Neale et al., 2012; O’Roak
et al., 2012; Sanders et al., 2012).
However, this process is complicated by
the fact that each of us inherits over 100
nonsense, loss-of-function mutations in
our genomes, leading to about 20 com-
pletely inactivated genes and several
dozen de novo variants, some of which
may be functional, but none of which are
clearly associated with disease (MacAr-
thur et al., 2012). In the latter category,
predicted protein structure altering rare
variants have been observed to be more
frequent in ASD cases, and recent work
suggests nontransmitted, de novo muta-
tions that delete genic regions, perturb
splicing, or truncate protein products
may contribute to the development of
ASD in 15%–20% of cases (Devlin and
Scherer, 2012). Although inherited muta-
tions have been identified in rare families,
no population-based exome sequencing
study has demonstrated a significant role
for inherited deleterious variants in ASD
risk, leaving the contribution of this class
of genetic variation unknown. Now, as
shown in two papers in this issue of
Neuron (Lim et al., 2013; Yu et al., 2013),
it is clear that ASD risk is increased when
two rare variants deleteriously affect
both copies of a protein coding gene, con-
sistent with a role for recessive inheritance
of nonsynonymous mutations in ASD.
Starting with a population-based ap-
proach, Lim et al. (2013) performed WES
in 933 ASD cases and 869 controls, allow-
ing them to see the complete genome
sequence in protein-coding and flank-
ing regions. They focused on the mostNeuron 77damaging type of mutations (nonsense
and essential splice site) transmitted
from the mother and father to the child.
In autosomes, they studied loci where
the mutations truncate both copies of
a protein, and in the X chromosome in
males, they studied mutations that trun-
cate the only copy. Only rare alleles of
this type (minor allele frequency %5%)
were studied, based on the hypothesis
that double mutations commonly found
in the population are not pathological.
These rare, putative recessively acting
mutations were observed twice as many
times in ASD patients as controls in auto-
somes (6% of cases and 3.3% of controls
carried such a mutation). When overlap-
ped with a data set of brain gene expres-
sion, the overall odds-ratio (OR) for ASD
increased to 2.7. Importantly, this enrich-
ment of double mutation variants was
replicated in an independent data set,
this time showing a smaller, but still signif-
icant effect (7.6% of cases and 5.5% of
controls). The authors estimate an overall
3% contribution to risk for ASD from this
class of mutations. Rare hemizygous
mutations on the X chromosome, which
would also be depleted of the normal
protein in males, were also enriched in
male ASD cases compared to controls
(4.8% versus 3.1%), revealing involve-
ment in 1.7% of male ASD cases. This
study fills an important gap in our knowl-
edge of the genetic architecture of ASD
by estimating that about 5%of ASD cases
may be affected by rare inherited loss-of-
function homozygous, compound hetero-
zygous, or X chromosome mutations in, January 23, 2013 ª2013 Elsevier Inc. 209
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Figure 1. Risk Imparted by Different Kinds of Rare Genetic Variants
The population-level enrichment in ASD versus controls of each form of rare
mutation studied to date (representative single nucleotide variant, or SNV esti-
mates from Sanders et al., 2012 but also see Neale et al., 2012; O’Roak et al.,
2012; Iossifov et al., 2012; copy number variation, or CNV estimates from
Sanders et al., 2012; two-hit transmitted SNV estimates from Lim et al.,
2013). An emerging trend in ASD genetics is that the most damaging types
of rare variation are observed more often in ASD than controls. De novo vari-
ants are overrepresented in autism more than transmitted variants. Moreover,
the most damaging class of variants have the greatest degree of overrepre-
sentation. These risk estimates do not include confidence intervals or all of
the studies but attempt to convey the relative effect sizes. Below the bar graph
are diagrams illustrating the method of inheritance and type of mutation.
Neuron
Previewsmales. In this way, Lim et al.
(2013) significantly advance
our population-level under-
standing of risk for ASD.
One key issue is that most
current studies on the contri-
bution of rare variants to
genetic risk are not well
powered to identify specific
genes. Typically, functional
studies or repeated instances
of rare mutations in the same
gene are needed to ensure
that a variant is indeed func-
tional and associated with
ASD. Alternatively, other evi-
dence, such as gene expres-
sion data can be used to
functionally prioritize variants,
as many mutations, including
but not limited to de novo
deletions (e.g., copy number
variations; CNVs), or reces-
sive mutations causing intel-
lectual disability (ID) or ASD
are expected to significantly
reduce RNA levels even in
peripheral blood (Luo et al.,
2012). We predict that future
studies combining genome
sequencing with gene ex-
pression will have increased
power to detect pathogenic
inherited or de novo genetic
variation. Short of this, verylarge sample sizes (larger than current
GWAS samples ranging 10,000 sub-
jects) or unique families with multiple
affected children (multiplex families) will
be necessary.
In the second study, Yu et al. (2013)
took an elegant approach to identify
specific inherited rare variants by study-
ing multiplex families, combining multiple
gene-mapping modalities, and validating
variant pathogenicity experimentally.
Specifically, the authors searched con-
sanguineous and/or multiplex families
using a combination of heterozyogsity
mapping and linkage-directed WES anal-
ysis. This identified regions in three fami-
lies with high linkage scores (likelihood
>600:1 of the genetic region containing
a variant tracking ASD in that family)
where specific nonsynonymous or frame-
shift rare variants were also found.
This analysis identified three genes,
AMT, PEX7, and SYNE1 as affected by210 Neuron 77, January 23, 2013 ª2013 Elsehomozygous or compound heterozygous
rare variation linked to ASD. To demon-
strate the pathogenicity of each of these
rare variants, the authors performed
detailed in vitro functional analysis, which
has not been previously performed in
population-based WES studies. For
example, one family contained a homozy-
gous I308F change in AMT, a gene coding
for a glycine-degradation enzyme in
which severe mutations have been shown
to lead to neonatal nonketotic hypogly-
cemia (NKT), a life-threatening neonatal
metabolic syndrome. This mutation was
analyzed biochemically and its effect
on protein solubility was evaluated in
bacteria, suggesting that the mutation
may induce a protein-folding defect
and result in a functional hypomorph.
Indeed, the family contained three
affected individuals with an atypical,
milder manifestation of NKT symptoms
in addition to ASD. The authors proposevier Inc.that, in general, less severe
mutations in genes involved
in recessive neurodevelop-
mental ID syndromes may
lead to ASD.
A similar inheritance pat-
tern and relationship to syn-
dromic disease was observed
with PEX7, which is the
causative gene for rhizomelic
chondrodysplasia punctata,
and SYNE1, where null muta-
tions have been linked to
cerebellar ataxia and a
recessive form of arthrogry-
posis multiplex congenita.
The functional data pre-
sented by the authors and
absence of the strong clas-
sical phenotypes suggested
these changes were also hy-
pomorphic, and their experi-
mental investigations suppor-
ted this. Yu and colleagues’
approach exemplifies how
various lines of direct and
indirect evidence—genome-
wide linkage, exonic variation,
biological validation, and
clinical relevance to existing
syndromes—may be used to
convincingly implicate a rare
variant, which itself may
never reach population-wide,
genome-wide significance.Yu et al. (2013) further generalized this
mutational pattern and its relationship to
syndromic disease by compiling a set of
risk genes comprising these 3 and 70
other previously implicated ID-related
genes. They then compared rare inherited
variants from WES in 163 consanguin-
eous and/or multiplex families to 831 pop-
ulation-matched individual exomes to
find additional homozygous, compound
heterozygous, or hemizygous rare muta-
tions. They find five families with previ-
ously unidentified nonsense or frameshift
variants and 11 with previously unidenti-
fied missense variants in their set of risk
genes. Intriguingly, two families had
nonsense or frameshift mutations in PAH
and one had a likely functional missense
mutation in AMT, suggesting a potential
metabolic contribution to their phenotype
and perhaps autistic symptoms. This
highlights the potential for better genetic
diagnoses and treatment by immediate
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Figure 2. The Percentage of Variance Explained by
Various Forms of Genetic Risk Factors for ASD
Common variants capture a large percentage of population
risk for ASD (Klei et al., 2012), whereas current studies show
that rare exonic variants explain a smaller amount of variance.
Percent variance explained for rare variants, based on cited
references in Figure 1, is estimated via the squared correlation
of outcome with predicted probabilities from logistic regres-
sion (Hosmer and Lemeshow, 2000). Note that though
common variants explain a large proportion of the variance,
each locus is expected to be of small effect, whereas, though
rare variants explain a small proportion of the variance, each
locus is expected to be of larger effect. As-yet-unexplored
rare variation (in the 98% of the genome not studied by
WES), interactions among genes, and the influence of the envi-
ronment are potential culprits to explain the remaining risk.
Additionally, because syndromic forms of autism are typically
excluded frommost population-level studies fromwhich these
genetic estimates have been derived, they are not included
here. Clinical ascertainment suggests that their prevalence is
on the order of 5% within the entire population of autism.
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was recently highlighted in a recently
discovered metabolic form of ASD
(Novarino et al., 2012). In total, this
study’s cohort found novel changes
linked to ASD in the novel genes
AMT, PEX7, SYNE1, VPS13B/
COH1, PAH, and POMGNT1, as
well as previously implicated genes
NLGN4X and MECP2.
These studies provide two unique
vistas on ASD genetics. Given an
etiologically and phenotypically
heterogeneous neurodevelopmental
disorder that may involve hundreds
of genes, the field has attempted to
gain a foothold on biological path-
ways by identifying genes using
highly penetrant mutations that are
linked to ASD. These studies also
provide convincing statistical evi-
dence for the role of homozygous or
compound heterozygous loss of
functionmutations inASDrisk.More-
over, the results emphasizehowdiffi-
cult it can be to assign blame to a
singlegene,given the rarityof events,
their occurrence in controls, and the
numbers necessary to attain gen-
ome-wide significance. Observing
the eventmore times in affected indi-
viduals is still necessary to provide
definitive proof of genetic associa-
tionwith disease. This is further com-plicated by the observation that mutation
rates vary by several orders of magnitude
across the genome, which suggests the
need for locus-specific calculations of
variant significance in ASD (Michaelson
et al., 2012).
Finally, the clearly defined role for CNVs
and SNVs that delete or alter either one or
both copies of a gene or its isoforms indi-
cates that transcript levels play a signifi-
cant role in ASD susceptibility. From this
perspective, we predict that future work
will identify variants in regulatory regions
that affect transcript levels, such as
promoters and enhancers, and that non-
coding regions will be just as functionally
important to ASD as currently implicated
protein-coding regions. This is also sup-ported by the high mutability of DNase
hypersensitive sites and CpG-rich regions
(Michaelson et al., 2012). So far, the
contribution of regulatory elements is
unexplored at a population level, as
WES does not effectively measure these
regions. Nevertheless, these current ap-
proaches provide unprecedented insight
(e.g., Figure 2) that will aid in explaining
ASD’s pathobiology.
REFERENCES
Anney, R., Klei, L., Pinto, D., Almeida, J., Bacchelli,
E., Baird, G., Bolshakova, N., Bo¨lte, S., Bolton,
P.F., Bourgeron, T., et al. (2012). Hum. Mol. Genet.
21, 4781–4792.
Berg, J.M., and Geschwind, D.H. (2012). Genome
Biol. 13, 247.Neuron 77, JanuDevlin, B., and Scherer, S.W. (2012). Curr.
Opin. Genet. Dev. 22, 229–237.
Hallmayer, J., Cleveland, S., Torres, A., Phil-
lips, J., Cohen, B., Torigoe, T., Miller, J., Fe-
dele, A., Collins, J., Smith, K., et al. (2011).
Arch. Gen. Psychiatry 68, 1095–1102.
Hosmer, D., and Lemeshow, S. (2000).
Applied Logic Regression, Second Edition
(New York: John Wiley & Sons, Inc.), pp.
164–167.
Iossifov, I., Ronemus, M., Levy, D., Wang,
Z., Hakker, I., Rosenbaum, J., Yamrom, B.,
Lee, Y.H., Narzisi, G., Leotta, A., et al.
(2012). Neuron 74, 285–299.
Klei, L., Sanders, S.J., Murtha, M.T., Hus, V.,
Lowe, J.K., Willsey, A.J., Moreno-De-Luca,
D., Yu, T.W., Fombonne, E., Geschwind,
D., et al. (2012). Mol. Autism 3, 9.
Lim, E.T., Raychaudhuri, S., Sanders, S.J.,
Stevens, C., Sabo, A., MacArthur, D.G.,
Neale, B.M., Kirby, A., Ruderfer, D.M.,
Fromer, M., et al. (2013). Neuron 77, this
issue, 235–242.
Luo, R., Sanders, S.J., Tian, Y., Voineagu, I.,
Huang, N., Chu, S.H., Klei, L., Cai, C., Ou, J.,
Lowe, J.K., et al. (2012). Am. J. Hum. Genet.
91, 38–55.
MacArthur, D.G., Balasubramanian, S.,
Frankish, A., Huang, N., Morris, J., Walter,
K., Jostins, L., Habegger, L., Pickrell, J.K.,
Montgomery, S.B., et al.; 1000 Genomes
Project Consortium. (2012). Science 335,
823–828.
Michaelson, J.J., Shi, Y., Gujral, M., Zheng,
H., Malhotra, D., Jin, X., Jian, M., Liu, G.,
Greer, D., Bhandari, A., et al. (2012). Cell
151, 1431–1442.Neale, B.M., Kou, Y., Liu, L., Ma’ayan, A., Samo-
cha, K.E., Sabo, A., Lin, C.F., Stevens, C., Wang,
L.S., Makarov, V., et al. (2012). Nature 485,
242–245.
Novarino, G., El-Fishawy, P., Kayserili, H., Meguid,
N.A., Scott, E.M., Schroth, J., Silhavy, J.L., Kara,
M., Khalil, R.O., Ben-Omran, T., et al. (2012).
Science 338, 394–397.
O’Roak, B.J., Vives, L., Girirajan, S., Karakoc, E.,
Krumm, N., Coe, B.P., Levy, R., Ko, A., Lee, C.,
Smith, J.D., et al. (2012). Nature 485, 246–250.
Sanders, S.J., Murtha, M.T., Gupta, A.R.,
Murdoch, J.D., Raubeson, M.J., Willsey, A.J.,
Ercan-Sencicek, A.G., DiLullo, N.M., Parikshak,
N.N., Stein, J.L., et al. (2012). Nature 485, 237–241.
Yu, T.W., Chahrour, M.H., Coulter, M.E., Jiraler-
spong, S., Okamura-Ikeda, K., Ataman, B.,
Schmitz-Abe, K., Harmin, D.A., Adli, M., Malik,
A.N., et al. (2013). Neuron 77, this issue,
259–273.ary 23, 2013 ª2013 Elsevier Inc. 211
